Health Care

About the CXO Plunge After Biden Signed National Biotechnology and Biomanufacturing Initiative

CXO plunged after Biden signed the National Biotechnology and Biomanufacturing Initiative. As tensions between China and US escalate, it is no longer possible to think on the basis of "common sense".

Thematic (Sector/Industry)
212 Views, 19 Sep 2022 08:46
Xinyao has highlighted this Insight as a Top Pick
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Data & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)
  • China Healthcare Weekly (Sep.30) - Orthopedics VBP, CGT CDMO, Surgical Robots, Bottom of HKEX
    02 Oct 2022
  • Joinn Laboratories (6127.HK) 22H1 - It's Time to Face Reality Before the Magic of Monkeys Disappears
    29 Sep 2022
  • China Healthcare Weekly (Sep.25) - CXO Trading Strategy, Plunge in Medical Beauty, Belief in Biotech
    26 Sep 2022
  • About the CXO Plunge After Biden Signed National Biotechnology and Biomanufacturing Initiative
    19 Sep 2022
  • PCAOB and CSRC‘s Agreement on Audit Terms Could Fail - The Real Test of China ADRs Lies Ahead
    08 Sep 2022
  • US-China Decoupling: The Impact on China Healthcare
    25 Aug 2022
  • Wuxi Biologics (2269.HK) 2022H1 - Hard to Achieve V-Share Rebound
    22 Aug 2022
x